rhBNP对急性心衰患者心功能、hsCRP和MMP-9水平的影响

Influence of rhBNP on cardiac function,levels of hsCRP and MMP-9 in patients with acute heart failure

目的:评价重组人脑利钠肽(rhBNP,新活素)治疗急性心力衰竭(AHF)患者的临床疗效及机制。方法:90例AHF患者被随机均分为rhBNP组(常规治疗基础上静脉注射rhBNP 3d)及常规治疗组。检测两组治疗前后左室射血分数(LVEF)、血清超敏C反应蛋白(hsCRP)、基质金属蛋白酶-9(MMP-9)水平并进行比较。结果:与治疗前比较,治疗后两组LVEF明显升高,hsCRP、MMP-9水平明显降低(P<0.05或<0.01);治疗后与常规治疗组比较,rhBNP组LVEF[(41.4±12.8)%比(51.3±13.9)%]升高更显著,hsCRP[(8.63±3.57)mg/L比(6.67±3.97)mg/L]、MMP-9[(17.89±4.75)mg/L比(14.64±4.89)mg/L]水平降低更显著(P<0.05或<0.01)。结论:rhBNP治疗急性心力衰竭效果显著,其机制可能与降低hsCRP、MMP-9水平有关。

Objective：To evaluate the clinical therapeutic effect and mechanism of recombinant human brain natriuretic peptide（rhBNP,Xinhuosu）in patients with acute heart failure（AHF）.Methods：A total of 90 AHF patients were randomly and equally divided into rhBNP group（received intravenous injection of rhBNP based on routine treatment for 3d）and routine treatment group.Left ventricular ejection fraction（LVEF）,levels of serum high sensitive C reactive protein（hsCRP）and matrix metalloproteinase-9（MMP-9）were measured and compared between two groups before and after treatment.Results：Compared with before treatment,after treatment,LVEF significantly rose,levels of hsCRP and MMP-9significantly reduced in both groups,P〈0.05or0.01;compared with routine treatment group after treatment,there was significant rise in LVEF[（41.4±12.8）% vs.（51.3±13.9）%],and significant reductions in levels of hsCRP[（8.63±3.57）mg/L vs.（6.67±3.97）mg/L]and MMP-9[（17.89±4.75）mg/L vs.（14.64±4.89）mg/L]in rhBNP group,P〈0.05or0.01.Conclusion：The rhBNP possesses significant therapeutic effect on acute heart failure,and its mechanism may be related with reducing hsCRP and MMP-9levels.